Dr Than Hein

MBBS, MRCP(UK), MMed(Int Med), FRCPath(UK), FAMS

Senior Consultant

Singapore General Hospital

Specialty/Department: Haematology

Clinical Interest: Acute Leukemia, Myeloproliferative Neoplasm, Haematopoietic Stem Cell ＆ Cellular Therapy

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukaemia, Aplastic Anaemia, Chronic lymphocytic leukemia, Chronic Myeloid Leukaemia, Haematopoietic Stem Cell Transplant, Lymphoma, Multiple Myeloma, Myelodysplastic Neoplasm (MDS), Myelofibrosis, Myeloproliferative Neoplasms.

Make an Appointment

Clinical Appointments

Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
Senior Consultant Haematology Singapore General Hospital
Senior Consultant National Cancer Centre Singapore

Academic Appointments

Clinical Lecturer, Yong Loo Lin School of Medicine, National University of Singapore
Clinical Assistant Professor, Duke-NUS Medical School Singapore

Profile

Dr Than Hein is a Senior Consultant with the Department of Haematology at Singapore General Hospital, and a Clinical Assistant Professor at the Duke-NUS Medical School Singapore. His sub-specialty… View More +

Education

FRCPath (UK) (RCPath, United Kingdom) 2016
FAMS (Singapore) 2015
MMed (Int Med) (NUS, Singapore) 2011
MRCP (UK) (RCP, United Kingdom) 2010

Professional Appointments and Committee Memberships

Head, Haematology Molecular Laboratory, Singapore General Hospital
Lead, Diagnostics, SingHealth Duke-NUS Blood Cancer Centre (SDBCC) Executive Committee
Lead, Chronic Myeloid Leukaemia, SingHealth Duke-NUS Blood Cancer Centre (SDBCC) Executive Committee
Clinical Assistant Professor, Duke-NUS Medical School Singapore
Clinical Lecturer, Yong Loo Lin School of Medicine, National University of Singapore
Clinical Core Faculty Member, National Haematology Senior Residency Training Programme

View More +

Awards

SingHealth Publish! Award (2021)
Faculty Appreciation Award, SingHealth Residency Programme (2020/2021)
Outstanding Faculty Award, SingHealth Residency Programme (2019/2020)
Khoo Pilot Research Award (Collaborative), SingHealth Duke-NUS Medicine Academic Medicine Programme (2019)
Nurturing Clinician Scientist Scheme (NCSS) Award, SingHealth Duke-NUS Medicine Academic Medicine Programme (2018)
10-Years Long Service Award, Singapore General Hospital (2018)
Special Recognition Award as a Role Model to the Medicine Graduating Class of 2018, National University of Singapore (2018)
National Medical Research Council Singapore, Research Training Fellowship (2016)
SingHealth Health Manpower Development Plan (HMDP) Award (2015)
Singapore Health Quality Service Award (STAR category) (2015)
Singapore Health Quality Service Award (2014)
Service with a Heart Award (2008, 2014)

View More +

Research Interests

Leukaemia and myeloid neoplasms
Genomics in leukaemia
Haematopoietic stem cell and regeneration

Publications

Selected Publications

Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL et al. A single-cell atlas identifies pre-treatment features of primary imatinib resistance in chronic myeloid leukemia. Blood. 2023 Mar. Online ahead of print. PMID: 36857629
Yan D, Franzini A, Pomicter AD, Halverson BJ, Antelope O, Mason CC, et al. SIRT 5 is a druggable metabolic vulnerability in acute myeloid leukemia. Blood cancer Discov. 2021 May;2(3):266–87.
Pwint K-SW, Chen Y, Diong CP, Goh Y-T, Grant D, Ho A, et al. Mobilization kinetics of peripheral blood stem cells with rescue plerixafor - real-world experience from a single center. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 1740–3.
Sinnakannu JR, Lee KL, Cheng S, Li J, Yu M, Tan SP, et al. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. Leukemia. 2020 Jul;34(7):1787–98.
Than H, Pomicter AD, Yan D, Beaver LP, Eiring AM, Heaton WL, et al. Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. Vol. 34, Leukemia. 2020. p. 1679–83.
Lam Yi H, Than H, Sng C, Cheong MA, Chuah C, Xiang W. Lysosome Inhibition by Mefloquine Preferentially Enhances the Cytotoxic Effects of Tyrosine Kinase Inhibitors in Blast Phase Chronic Myeloid Leukemia. Transl Oncol. 2019 Sep;12(9):1221–8.
Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, et al. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv. 2019 Oct;3(20):2949–61.
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. 2019 Oct;36(4):431-443.e5.
Zhang H, Wilmot B, Bottomly D, Dao K-HT, Stevens E, Eide CA, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 Sep;134(11):867–79.
Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina A V, Ahmann JM, et al. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin cancer Res an Off J Am Assoc Cancer Res. 2019 Apr;25(7):2323–35.
Than H, Lye WK, Sng C, Allen JCJ, Ong ST, Chuah C. BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients. Vol. 60, Leukemia & lymphoma. United States; 2019. p. 234–7.
Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, et al. Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. Leukemia. 2018 Sep;32(9):2049–54.
Ong SY, Chin YA, Than H, Tan CW, Yap ES, Wong WH, et al. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence. Vol. 96, Annals of hematology. Germany; 2017. p. 525–7.
Than H, Loh JBE, Sum CLL, Ng HJ. Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report. Vol. 68, Journal of clinical pathology. England; 2015. p. 318–9.
Xiang W, Cheong JK, Ang SH, Teo B, Xu P, Asari K, et al. Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration. Oncotarget. 2015 Oct;6(32):33769–80.
Ng KP, Hillmer AM, Chuah CTH, Juan WC, Ko TK, Teo ASM, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012 Mar;18(4):521–8.